Do I need a prescription for Dosulepin 25mg/5ml oral solution?

Dosulepin 25mg/5ml oral solution is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Dosulepin 25mg/5ml oral solution?

Dosulepin 25mg/5ml oral solution is the generic name. It is available under brand names including: Dosulepin 25mg/5ml oral solution. (Source: NHS dm+d — Actual Medicinal Products)

Dosulepin 25mg/5ml oral solution

Prescription only

Requires a prescription from a doctor or prescriber

Oral solution

25mg/5ml

Oral

Active ingredients:

Dosulepin

BNF classificationBrowse formulary

Where this medicine sits in the British National Formulary — the UK's standard prescribing reference

BNF 04.03.01

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC N06AA16

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Check interactions for Dosulepin

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Official medicine documents

Yellow Card

Report side effects (MHRA)

Drug safety updates

MHRA alerts for Dosulepin

Source: MHRA Products DatabaseOGL 3.0

Updated 3 months ago(16 Jan 2026)

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Dosulepin

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Dosulepin

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

1 branded products available

1 productsShow details

1 products

Possibly available on the UK marketRestricted supplyDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Dosulepin on the MHRA register

Dosulepin 25mg/5ml oral solution

Drug Tariff Special Order

None

Special

Source: NHS dm+dOGL 3.0

Updated about 1 month ago(1 Mar 2026)

Price & daily doseShow details

£0.11indicative price

This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.

View full Drug Tariff

Source: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.

WHO defined daily dose (DDD)

150 mg

Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.

Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.

Therapeutically similar medicines

10 similarShow details

Nortriptyline 25mg capsules

Capsule

25mg

Same therapeutic group

Nortriptyline 10mg capsules

Capsule

10mg

Same therapeutic group

Nortriptyline 10mg/5ml oral solution sugar free

Oral solution

10mg/5ml

Same therapeutic group

Nortriptyline 25mg/5ml oral solution sugar free

Oral solution

25mg/5ml

Same therapeutic group

Clomipramine 250mg/5ml oral suspension

Oral suspension

250mg/5ml

Same therapeutic group

Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Show details

Loading prescribing data...

Clinical guidelines and formulary information

British National Formulary

Dosulepin

BNF

Drug monograph — bnf.nice.org.uk

Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.

NICE clinical guidance(1)

Depression in adults with a chronic physical health problem: recognition and management (CG91)

CG91

Clinical guideline

Updated Oct 2009

Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.

Check stock at pharmacies and supply information

Show details

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & product information

Official product databases and supply status monitoring

Shortages info

NHS Specialist Pharmacy Service (SPS)

emc product search

Discontinuations & alternatives for Dosulepin

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.

Codes for healthcare professionals and prescribing systems

Show details

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

8454311000001101

dm+d ID

8454311000001101

VTM (Virtual Therapeutic Moiety)

775693007

VMP (Virtual Medicinal Product)

8454311000001101

BNF code

04030100

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

N06AA16

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Show details

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

15 found

Half-life

20.4 hours

Mechanism

By binding to noradrenaline transporter (NAT) and serotonin transporter (SERT) i…

Food interactions

None known

Human targets

12 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

37.6ng/mL

Dosulepin is well absorbed from the intestines to reach the peak plasma concentration of 37.6ng/mL…

Half-life

20.4 hours

The elimination half life is approximately 20.4 hours following oral administration of 25mg dosulepin .
[L881]

Protein binding

84%

Approximately 84% of unchanged drug is bound to serum protein .
[L882]

Volume of distribution

45 L/kg

The mean apparent Vd is approximately 45 L/kg after oral administration of 75mg dosulepin .
[A19753]…

Metabolism

Dosulepin undergoes extensive hepatic metabolism, to form main metabolites N-demethylated derivative northiaden (desmethyldosulepin or northiaden) and dosulepin S-oxide.…

Elimination

50%

Dosulepin is predominantly cleared via renal elimination, mainly in the form of metabolites.…

Clearance

1.36 L/kg

Oral clearance is approximately 1.36 L/kg * hr following a single oral dose of 75mg dosulepin .
[A19753]

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Investigational

Small molecule

About this compound

Dosulepin (INN, BAN) formerly known as dothiepin (USAN), is a tricyclic antidepressant with anxiolytic properties that is used in several European and South Asian countries, as well as Australia, South Africa, and New Zealand. It is not FDA-approved due to low therpeutic index and significant toxicity in overdose. Dosulepin inhibits the reuptake of biogenic amines, increasing available neurotransmitter levels at the synaptic cleft. The use of dosulepsin is only recommended in patients who are intolerant or unresponsive to alternative antidepressant therapies. Dosulepsin is a thio derivative of DB00321 with a similar efficacy to that of DB00321, and also exhibits anticholinergic, antihistamine and central sedative properties [L882].
Its hydrochloride form is a common active ingredient in different drug formulations.

Properties:

solid

Avg. mass: 295.44 Da

DrugBank indication

Indicated in the treatment of symptoms of depressive illness, especially where an anti-anxiety effect is required.

Also known as(112)

(3E)-3-dibenzo[b,e]thiepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine

11-(3-Dimethylaminopropylidene)-6,11-dihydrodibenzo(b,e)thiepin

Dosulepin

Dosulepina

Dosulépine

Dosulepinum

Dothiepin

trans-dothiepin

Dosage forms(5)

Tablet (Oral)

Tablet (Oral) — 75 MG

Capsule (Oral) — 25 MG

Pill (Oral) — 75 MG

Tablet, film coated (Oral) — 75 MG

Molecular properties(18)

Drug interactions(1770)

Known interactions with other medications. Always consult a healthcare professional.

Cilostazol

Unknown severity

DB01166

The serum concentration of Cilostazol can be increased when it is combined with Dosulepin.

Check this interaction

Remikiren

Moderate

DB00212

Dosulepin may decrease the antihypertensive activities of Remikiren.

Check this interaction

Guanadrel

Moderate

DB00226

Dosulepin may decrease the antihypertensive activities of Guanadrel.

Check this interaction

Olmesartan

Moderate

DB00275

Dosulepin may decrease the antihypertensive activities of Olmesartan.

Check this interaction

Nitroprusside

Moderate

DB00325

Dosulepin may decrease the antihypertensive activities of Nitroprusside.

Check this interaction

Minoxidil

Moderate

DB00350

Dosulepin may decrease the antihypertensive activities of Minoxidil.

Check this interaction

Nisoldipine

Moderate

DB00401

Dosulepin may decrease the antihypertensive activities of Nisoldipine.

Check this interaction

Prazosin

Moderate

DB00457

Dosulepin may decrease the antihypertensive activities of Prazosin.

Check this interaction

Fosinopril

Moderate

DB00492

Dosulepin may decrease the antihypertensive activities of Fosinopril.

Check this interaction

Trandolapril

Moderate

DB00519

Dosulepin may decrease the antihypertensive activities of Trandolapril.

Check this interaction

Benazepril

Moderate

DB00542

Dosulepin may decrease the antihypertensive activities of Benazepril.

Check this interaction

Enalapril

Moderate

DB00584

Dosulepin may decrease the antihypertensive activities of Enalapril.

Check this interaction

Cyclothiazide

Moderate

DB00606

Dosulepin may decrease the antihypertensive activities of Cyclothiazide.

Check this interaction

Bisoprolol

Moderate

DB00612

Dosulepin may decrease the antihypertensive activities of Bisoprolol.

Check this interaction

Candoxatril

Moderate

DB00616

Dosulepin may decrease the antihypertensive activities of Candoxatril.

Check this interaction

Eplerenone

Moderate

DB00700

Dosulepin may decrease the antihypertensive activities of Eplerenone.

Check this interaction

Lisinopril

Moderate

DB00722

Dosulepin may decrease the antihypertensive activities of Lisinopril.

Check this interaction

Nitroglycerin

Moderate

DB00727

Dosulepin may decrease the antihypertensive activities of Nitroglycerin.

Check this interaction

Cryptenamine

Moderate

DB00785

Dosulepin may decrease the antihypertensive activities of Cryptenamine.

Check this interaction

Fenoldopam

Moderate

DB00800

Dosulepin may decrease the antihypertensive activities of Fenoldopam.

Check this interaction

Tadalafil

Moderate

DB00820

Dosulepin may decrease the antihypertensive activities of Tadalafil.

Check this interaction

Eprosartan

Moderate

DB00876

Dosulepin may decrease the antihypertensive activities of Eprosartan.

Check this interaction

Quinapril

Moderate

DB00881

Dosulepin may decrease the antihypertensive activities of Quinapril.

Check this interaction

Telmisartan

Moderate

DB00966

Dosulepin may decrease the antihypertensive activities of Telmisartan.

Check this interaction

Deserpidine

Moderate

DB01089

Dosulepin may decrease the antihypertensive activities of Deserpidine.

Check this interaction

Diazoxide

Moderate

DB01119

Dosulepin may decrease the antihypertensive activities of Diazoxide.

Check this interaction

Terazosin

Moderate

DB01162

Dosulepin may decrease the antihypertensive activities of Terazosin.

Check this interaction

Guanethidine

Moderate

DB01170

Dosulepin may decrease the antihypertensive activities of Guanethidine.

Check this interaction

Epoprostenol

Moderate

DB01240

Dosulepin may decrease the antihypertensive activities of Epoprostenol.

Check this interaction

Hydralazine

Moderate

DB01275

Dosulepin may decrease the antihypertensive activities of Hydralazine.

Check this interaction

Cilazapril

Moderate

DB01340

Dosulepin may decrease the antihypertensive activities of Cilazapril.

Check this interaction

Saprisartan

Moderate

DB01347

Dosulepin may decrease the antihypertensive activities of Saprisartan.

Check this interaction

Spirapril

Moderate

DB01348

Dosulepin may decrease the antihypertensive activities of Spirapril.

Check this interaction

Dexpropranolol

Moderate

DB03322

Dosulepin may decrease the antihypertensive activities of Dexpropranolol.

Check this interaction

Tienilic acid

Moderate

DB04831

Dosulepin may decrease the antihypertensive activities of Tienilic acid.

Check this interaction

Ambrisentan

Moderate

DB06403

Dosulepin may decrease the antihypertensive activities of Ambrisentan.

Check this interaction

Diethylnorspermine

Moderate

DB06445

Dosulepin may decrease the antihypertensive activities of Diethylnorspermine.

Check this interaction

Pinacidil

Moderate

DB06762

Dosulepin may decrease the antihypertensive activities of Pinacidil.

Check this interaction

Temocapril

Moderate

DB08836

Dosulepin may decrease the antihypertensive activities of Temocapril.

Check this interaction

Riociguat

Moderate

DB08931

Dosulepin may decrease the antihypertensive activities of Riociguat.

Check this interaction

Macitentan

Moderate

DB08932

Dosulepin may decrease the antihypertensive activities of Macitentan.

Check this interaction

Aliskiren

Moderate

DB09026

Dosulepin may decrease the antihypertensive activities of Aliskiren.

Check this interaction

Trimazosin

Moderate

DB09206

Dosulepin may decrease the antihypertensive activities of Trimazosin.

Check this interaction

Rauwolfia serpentina root

Moderate

DB09363

Dosulepin may decrease the antihypertensive activities of Rauwolfia serpentina root.

Check this interaction

Enalaprilat

Moderate

DB09477

Dosulepin may decrease the antihypertensive activities of Enalaprilat.

Check this interaction

Selexipag

Moderate

DB11362

Dosulepin may decrease the antihypertensive activities of Selexipag.

Check this interaction

Angiotensin 1-7

Moderate

DB11720

Dosulepin may decrease the antihypertensive activities of Angiotensin 1-7.

Check this interaction

Imidapril

Moderate

DB11783

Dosulepin may decrease the antihypertensive activities of Imidapril.

Check this interaction

BQ-123

Moderate

DB12054

Dosulepin may decrease the antihypertensive activities of BQ-123.

Check this interaction

Zofenopril

Moderate

DB13166

Dosulepin may decrease the antihypertensive activities of Zofenopril.

Check this interaction

Showing 50 of 1770 interactions

Toxicity & overdose

High mortality is associated with overdose of dosulepin (>5mg/kg) with the onset of toxicity occuring within 4-6 hours. Dosulepin may increase the risk of cardiovascular toxicity (cardiac arrhythmias, conduction disorders, cardiac failure and circulatory collapse) and severe hypotension, especially in the elderly .
[L881]
Withdrawal symptoms are reported in case of sudden cessation of therapy, which include insomnia, irritability, headache, nausea, giddiness, panic-anxiety, extreme motor restlessness and excessive perspiration. There have been reports of increased suicidal thoughts or behaviour with dosulepin treatment.

Oral lowest published toxic dose (Toxic Dose Low, TDLo) is 90 mg/kg in infants and 4.5 mg/kg in female adults. Intravenous LD50 in mouse is 31 mg/kg MSDS.

Most common adverse effects involve the central nervous system (drowsiness, extrapyramidal symptoms, tremor, confusional states, disorientation, dizziness, paraesthesia, alterations to EEG patterns), anticholinergic effects (dry mouth, sweating, urinary retention), cardiovascular system (hypotension, postural hypotension, tachycardia, palpitations, arrhythmias, conduction defects), endocrine system (altered libido), gastrointestinal system (nausea, vomiting, constipation) and blurred vision .
[L882]

How it works

Mechanism of action

By binding to noradrenaline transporter (NAT) and serotonin transporter (SERT) in an equipotent manner and inhibiting the reuptake activity, dosulepin increases the free levels of noradrenaline and 5HT at the synaptic cleft. It is shown that the main metabolite northiaden is a more potent inhibitor of noradrenaline uptake than the parent drug [A19758].

Dosulepin displays affinity towards α2-adrenoceptors and to a lesser extent, α1-adrenoceptors [A6584]. Inhibition of presynaptic α2-adrenoceptors by dosulepin facilitates noradrenaline release and further potentiates the antidepressant effects [A19758]. It also downregulates central β-adrenoceptors by causing a decline in the number of receptors and reduces noradrenaline-induced cyclic AMP formation [L881][A19758].
Dosulepin binds to 5HT1A and 5HT2A receptors in the cerebral cortex and hippocampus as an antagonist. 5HT1A receptors are autoreceptors that inhibit 5HT release and 5HT2A receptors are Gi/Go-coupled receptors that reduces dopamine release upon activation T28. Antagonism at 5HT2A receptors may also improve sleep patterns. Dosulepin also binds to muscarinic acetylcholine receptors and causes antimuscarinic side effects such as dry mouth. By acting as an antagonist at histamine type 1 (H1) receptors, dosulepin mediates a sedative effect.

Main metabolites northiaden, dothiepin sulphoxide and northiaden sulphoxide may also bind to 5HT, α2 and H1 receptors, although with less affinity compared to the parent drug [A19755].

Pharmacodynamics

Dosulepin is a tricyclic antidepressant that interacts with various receptors and transporters. It is a monoamine reuptake inhibitor with approximately equal potency for noradrenaline and 5-HT that increases the availability of these neurotransmitters at the central synapses [L882]. The metabolites of dosulepin are shown to inhibit 5HT uptake by the human blood platelet [A19753].

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

Dosulepin is well absorbed from the intestines to reach the peak plasma concentration of 37.6ng/mL at 2.18 hours (Tmax) following oral administration of 25mg .
[L881]
The steady state concentrations are variable among individuals due to dynamic relationship between the drug dose and plasma concentration .
[L882]

Half-life

The elimination half life is approximately 20.4 hours following oral administration of 25mg dosulepin .
[L881]

Protein binding

Approximately 84% of unchanged drug is bound to serum protein .
[L882]

Volume of distribution

The mean apparent Vd is approximately 45 L/kg after oral administration of 75mg dosulepin .
[A19753]
It crosses the blood-brain barrier to mediate its antidepressant actions and also crosses the placental barriers, with low concentration of the drug excreted in breast milk .
[L882]

Metabolism

Dosulepin undergoes extensive hepatic metabolism, to form main metabolites N-demethylated derivative northiaden (desmethyldosulepin or northiaden) and dosulepin S-oxide. Northiaden S-oxide is among 12 basic metabolites that are found in urine. The metabolic pathways of dosulepin is thought to involve N-demethylation, S-oxidation and glucuronic acid conjugation .
[L882]

Route of elimination

Dosulepin is predominantly cleared via renal elimination, mainly in the form of metabolites. Renal excretion of dosulepin and its metabolites accounts for 50% - 60% of total elimination, and biliary/fecal excretion is about 15%-40% .
[L881]

Clearance

Oral clearance is approximately 1.36 L/kg * hr following a single oral dose of 75mg dosulepin .
[A19753]

Drug targets(12)

Proteins and enzymes this drug interacts with in the body

5-hydroxytryptamine receptor 1A

BE0000291

HTR1A

antagonist

Specific functionG protein-coupled serotonin receptor activity

Cellular location

Cell membrane

General function & pharmacology

G-protein coupled receptor for 5-hydroxytryptamine (serotonin) .
PMID:22957663 PMID:3138543 PMID:33762731 PMID:37935376 PMID:37935377 PMID:8138923 PMID:8393041

Also functions as a receptor for various drugs and psychoactive substances .
PMID:22957663 PMID:3138543 PMID:33762731 PMID:38552625 PMID:8138923 PMID:8393041

Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase .
PMID:22957663 PMID:3138543 PMID:33762731 PMID:8138923 PMID:8393041

HTR1A is coupled to G(i)/G(o) G alpha proteins and mediates inhibitory neurotransmission: signaling inhibits adenylate cyclase activity and activates a phosphatidylinositol-calcium second messenger system that regulates the release of Ca(2+) ions from intracellular stores .
PMID:33762731 PMID:35610220
Beta-arrestin family members regulate signaling by mediating both receptor desensitization and resensitization processes .
PMID:18476671 PMID:20363322 PMID:20945968

Plays a role in the regulation of 5-hydroxytryptamine release and in the regulation of dopamine and 5-hydroxytryptamine metabolism .
PMID:18476671 PMID:20363322 PMID:20945968

Plays a role in the regulation of dopamine and 5-hydroxytryptamine levels in the brain, and thereby affects neural activity, mood and behavior .
PMID:18476671 PMID:20363322 PMID:20945968

Plays a role in the response to anxiogenic stimuli PMID:18476671 PMID:20363322 PMID:20945968

5-hydroxytryptamine receptor 2A

BE0000451

HTR2A

antagonist

Specific function1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding

Cellular location

Cell membrane

General function & pharmacology

G-protein coupled receptor for 5-hydroxytryptamine (serotonin) .
PMID:1330647 PMID:18703043 PMID:19057895 PMID:21645528 PMID:22300836 PMID:35084960 PMID:38552625

Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD) .
PMID:28129538 PMID:35084960
Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors .
PMID:28129538 PMID:35084960
HTR2A is coupled to G(q)/G(11) G alpha proteins and activates phospholipase C-beta, releasing diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) second messengers that modulate the activity of phosphatidylinositol 3-kinase and promote the release of Ca(2+) ions from intracellular stores, respectively .
PMID:18703043 PMID:28129538 PMID:35084960

Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways .
PMID:28129538 PMID:35084960
Affects neural activity, perception, cognition and mood .
PMID:18297054
Plays a role in the regulation of behavior, including responses to anxiogenic situations and psychoactive substances. Plays a role in intestinal smooth muscle contraction, and may play a role in arterial vasoconstriction (By similarity)

Histamine H1 receptor

BE0000442

HRH1

antagonist

Specific functionhistamine receptor activity

Cellular location

Cell membrane

General function & pharmacology

G-protein-coupled receptor for histamine, a biogenic amine that functions as an immune modulator and a neurotransmitter .
PMID:33828102 PMID:8280179
Through the H1 receptor, histamine mediates the contraction of smooth muscles and increases capillary permeability due to contraction of terminal venules. Also mediates neurotransmission in the central nervous system and thereby regulates circadian rhythms, emotional and locomotor activities as well as cognitive functions (By similarity)

Muscarinic acetylcholine receptor M1

BE0000092

CHRM1

antagonist

Specific functionG protein-coupled acetylcholine receptor activity

Cellular location

Cell membrane

General function & pharmacology

Muscarinic acetylcholine receptor M2

BE0000560

CHRM2

antagonist

Specific functionarrestin family protein binding

Cellular location

Cell membrane

General function & pharmacology

The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then triggers calcium ion release into the cytosol

Metabolizing enzymes(5)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

CYP2D6Cytochrome P450 2D6

substrate

inhibitor

CYP1A2Cytochrome P450 1A2

substrate

inhibitor

CYP3A4Cytochrome P450 3A4

substrate

CYP2C9Cytochrome P450 2C9

inhibitor

CYP2C19Cytochrome P450 2C19

substrate

inhibitor

Scientific references(5)

Lancaster S.G., Gonzalez J.P.

Dothiepin.

Drugs

198938(1):123-147. doi: 10.2165/00003495-198938010-00005

PMID: 2670509 DOI: 10.2165/00003495-198938010-00005

Maguire K.P., Burrows G.D., Norman T.R., Scoggins B.A.

Metabolism and pharmacokinetics of dothiepin..

British Journal of Clinical Pharmacology

198112(3):405-409. doi: 10.1111/j.1365-2125.1981.tb01235.x

PMID: 7295471 DOI: 10.1111/j.1365-2125.1981.tb01235.x

Fulton A., Norman T.R., Cheng H., Burrows G.D.

Assessment of the antidepressant activity of dothiepin and its metabolites by preclinical tests.

Journal of Affective Disorders

19824(3):261-269. doi: 10.1016/0165-0327(82)90010-6

PMID: 6215444 DOI: 10.1016/0165-0327(82)90010-6

Gillman P.K.

Tricyclic antidepressant pharmacology and therapeutic drug interactions updated.

British Journal of Pharmacology

2007151(6):737-748. doi: 10.1038/sj.bjp.0707253

PMID: 17471183 DOI: 10.1038/sj.bjp.0707253

Heal D., Cheetham S., Martin K., Browning J., Luscombe G., Buckett R.

Comparative pharmacology of dothiepin, its metabolites, and other antidepressant drugs.

Drug Development Research

199227(2):121-135. doi: 10.1002/ddr.430270205

DOI: 10.1002/ddr.430270205

ATC classification(1 code)

ATC N06AA16

International brands(14)

Salt forms(1)

Dosulepin hydrochloride(DBSALT001822)

Experimental properties(3)

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Dosulepin

DB09167

CAS number

113-53-1

UNII (FDA)

W13O82Z7HL

InChI Key (molecular fingerprint)

PHTUQLWOUWZIMZ-GZTJUZNOSA-N

Additional database identifiers

ChEBI

36803

PubChem Compound

5284550

PubChem Substance

310265076

KEGG Drug

D07872

ChemSpider

4447605

Wikipedia

Dosulepin

ChEMBL

CHEMBL1492500

ZINC

ZINC000000020249

RxCUI

3634

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5286

GenAtlas

HTR1A

GeneCards

HTR1A

GenBank Gene Database

M28269

GenBank Protein Database

189928

IUPHAR

Guide to Pharmacology

UniProtKB

P08908

UniProt Accession

5HT1A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5293

GenAtlas

HTR2A

GeneCards

HTR2A

GenBank Gene Database

S42168

GenBank Protein Database

36431

IUPHAR

Guide to Pharmacology

UniProtKB

P28223

UniProt Accession

5HT2A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5182

GenAtlas

HRH1

GeneCards

HRH1

GenBank Gene Database

Z34897

GenBank Protein Database

510296

IUPHAR

262

Guide to Pharmacology

262

UniProtKB

P35367

UniProt Accession

HRH1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1950

GenAtlas

CHRM1

GeneCards

CHRM1

GenBank Gene Database

X52068

GenBank Protein Database

34451

IUPHAR

Guide to Pharmacology

UniProtKB

P11229

UniProt Accession

ACM1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1951

GenAtlas

CHRM2

GeneCards

CHRM2

GenBank Gene Database

M16404

GenBank Protein Database

177990

IUPHAR

Guide to Pharmacology

UniProtKB

P08172

UniProt Accession

ACM2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1952

GenAtlas

CHRM3

GeneCards

CHRM3

GenBank Gene Database

X15266

GenBank Protein Database

32324

IUPHAR

Guide to Pharmacology

UniProtKB

P20309

UniProt Accession

ACM3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1953

GenAtlas

CHRM4

GeneCards

CHRM4

GenBank Gene Database

M16405

GenBank Protein Database

61970253

IUPHAR

Guide to Pharmacology

UniProtKB

P08173

UniProt Accession

ACM4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1954

GenAtlas

CHRM5

GeneCards

CHRM5

GenBank Gene Database

M80333

GenBank Protein Database

177988

IUPHAR

Guide to Pharmacology

UniProtKB

P08912

UniProt Accession

ACM5_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:281

GenAtlas

ADRA2A

GeneCards

ADRA2A

GenBank Gene Database

M23533

GenBank Protein Database

178196

IUPHAR

Guide to Pharmacology

UniProtKB

P08913

UniProt Accession

ADA2A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:282

GenAtlas

ADRA2B

GeneCards

ADRA2B

GenBank Gene Database

M34041

GenBank Protein Database

178198

IUPHAR

Guide to Pharmacology

UniProtKB

P18089

UniProt Accession

ADA2B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:283

GenAtlas

ADRA2C

GeneCards

ADRA2C

GenBank Gene Database

J03853

GenBank Protein Database

178194

IUPHAR

Guide to Pharmacology

UniProtKB

P18825

UniProt Accession

ADA2C_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:277

GenAtlas

ADRA1A

GeneCards

ADRA1A

GenBank Gene Database

D25235

GenBank Protein Database

433201

IUPHAR

Guide to Pharmacology

UniProtKB

P35348

UniProt Accession

ADA1A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:278

GenAtlas

ADRA1B

GeneCards

ADRA1B

GenBank Gene Database

M99589

IUPHAR

Guide to Pharmacology

UniProtKB

P35368

UniProt Accession

ADA1B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:280

GenAtlas

ADRA1D

GeneCards

ADRA1D

GenBank Gene Database

M76446

GenBank Protein Database

177807

IUPHAR

Guide to Pharmacology

UniProtKB

P25100

UniProt Accession

ADA1D_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:11048

GenAtlas

SLC6A2

GeneCards

SLC6A2

GenBank Gene Database

M65105

GenBank Protein Database

189258

Guide to Pharmacology

926

UniProtKB

P23975

UniProt Accession

SC6A2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:11050

GenAtlas

SLC6A4

GeneCards

SLC6A4

GenBank Gene Database

X70697

GenBank Protein Database

36433

Guide to Pharmacology

928

UniProtKB

P31645

UniProt Accession

SC6A4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2625

GenAtlas

CYP2D6

GeneCards

CYP2D6

GenBank Gene Database

M20403

GenBank Protein Database

181350

Guide to Pharmacology

1329

UniProtKB

P10635

UniProt Accession

CP2D6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2596

GenAtlas

CYP1A2

GeneCards

CYP1A2

GenBank Gene Database

Z00036

Guide to Pharmacology

1319

UniProtKB

P05177

UniProt Accession

CP1A2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2637

GenAtlas

CYP3A4

GeneCards

CYP3A4

GenBank Gene Database

M18907

Guide to Pharmacology

1337

UniProtKB

P08684

UniProt Accession

CP3A4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2623

GenAtlas

CYP2C9

GeneCards

CYP2C9

GenBank Gene Database

AY341248

Guide to Pharmacology

1326

UniProtKB

P11712

UniProt Accession

CP2C9_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2621

GeneCards

CYP2C19

GenBank Gene Database

M61854

GenBank Protein Database

181344

Guide to Pharmacology

1328

UniProtKB

P33261

UniProt Accession

CP2CJ_HUMAN

DrugBank citations

If you use DrugBank data in your research, please cite the following publications:

Knox C., Wilson M., Klinger C.M., et al

DrugBank 6.

0: the DrugBank Knowledgebase for 2024

Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275

PMID: 37953279

Wishart D.S., Feunang Y.D., Guo A.C., et al

DrugBank 5.

0: a major update to the DrugBank database for 2018

Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082

PMID: 29126136

Show earlier publications

Law V., Knox C., Djoumbou Y., et al

DrugBank 4.

0: shedding new light on drug metabolism

Nucleic Acids Res. 2014 Jan 142(1):D1091-7

PMID: 24203711

Knox C., Law V., Jewison T., et al

DrugBank 3.

0: a comprehensive resource for 'omics' research on drugs

Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41

PMID: 21059682

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a knowledgebase for drugs, drug actions and drug targets.

Nucleic Acids Research

2008 Jan36(Database issue):D901-6

PMID: 18048412

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Nucleic Acids Research

2006 Jan 134(Database issue):D668-72

PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated 27 days ago(8 Mar 2026)

Back to medicines

Dosulepin 25mg/5ml oral solution

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

WHO defined daily dose (DDD)

British National Formulary

NICE clinical guidance(1)

Pharmacy stock checkers

Supply & product information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clearance

Clinical essentials

Pharmacology

Deep science
17

Chemical identifiers

Dosulepin

Additional database identifiers

DrugBank citations

Dosulepin 25mg/5ml oral solution

Safety & regulatory

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

NHS reimbursement price

WHO defined daily dose (DDD)

Medicines like this

Prescribing statistics

Guidance (NICE / BNF)

British National Formulary

NICE clinical guidance(1)

Availability, stocks & shortages

Pharmacy stock checkers

Supply & product information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clearance

Clinical essentials

Pharmacology

Deep science17

Chemical identifiers

Dosulepin

Additional database identifiers

DrugBank citations

Deep science
17